Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Here's the Biggest Problem Ocugen Faces Right Now

TheMotleyFool

0 0

Here's the Biggest Problem Ocugen Faces Right NowPhoto, wide shot, wide-angle lens, Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png

Ocugen (NASDAQ: OCGN) is a latecomer to the coronavirus vaccine race. It recently gained rights to co-commercialize Bharat Biotech's vaccine candidate in the U.S. In this Motley Fool Live video, recorded on Feb. 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss Ocugen's partnership with the India-based company -- and whether the companies can potentially carve out a share of the U.S. market.

Source Fool.com

Like: 0

OCGN

Share